Retatrutide + Cagrilintide
153,00$
description
This cutting-edge peptide combination merges Retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors, with Cagrilintide, a long-acting amylin analog, offering a multi-targeted approach to appetite regulation, energy expenditure, and fat metabolism. Together, these peptides have shown superior results in preclinical and early human studies for weight reduction, glucose control, and metabolic restoration—exceeding the effects of GLP-1 monotherapy. Epigenetix Labs supplies this advanced formulation in research-grade purity. For laboratory research use only. Not for human or veterinary use.
10 Research-Based Reasons to Study This Peptide Blend
- Activates GLP-1, GIP, and glucagon receptors for broad metabolic impact
- Synergistically suppresses appetite and reduces caloric intake
- Increases energy expenditure through glucagon receptor pathways
- Enhances insulin sensitivity and glucose tolerance
- Slows gastric emptying to increase satiety and postprandial control
- Reduces body weight and visceral fat in obesity models
- Preserves lean muscle mass during weight loss
- Improves lipid metabolism and fatty acid oxidation
- Targets multiple hypothalamic hunger pathways
- Exceeds the metabolic effects of GLP-1 analogs alone
Additional information
Additional information
| Weight | 0,006 kg |
|---|---|
| Dimensions | 1,5 × 1,5 × 3,5 cm |
| Scientific Background | Retatrutide is a synthetic peptide that acts as a GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptor agonist. This triple action enhances glucose homeostasis, suppresses appetite, and increases energy expenditure, particularly through hepatic and adipose tissue pathways. Cagrilintide is a chemically stabilized analog of human amylin, a hormone co-secreted with insulin that slows gastric emptying, promotes satiety, and reduces caloric intake. The pairing of Retatrutide and Cagrilintide targets central and peripheral metabolic pathways, making this blend ideal for obesity and metabolic research models seeking comprehensive bodyweight modulation. |
| Research Applications | This peptide blend is currently being studied in the fields of: • Obesity and severe overweight modeling |
| Key Research Findings | 1. A 2023 JAMA study showed Retatrutide alone led to a 24.2% mean bodyweight reduction in obese human subjects over 48 weeks—the highest recorded in any anti-obesity peptide to date. 2. In preclinical models, Retatrutide + Cagrilintide combination showed enhanced effects on satiety, insulin sensitivity, and fat oxidation compared to either peptide alone. 3. The combination affects multiple satiety centers in the hypothalamus, offering a strong dual signal to reduce hunger and improve energy balance. 4. Animal studies revealed significant fat mass loss with muscle mass preservation, making this blend ideal for body recomposition studies. 5. Cagrilintide adds amylin-mediated delay of gastric emptying, enhancing the glycemic and appetite-control effects of Retatrutide. |
| Purity & Manufacturing Standards | Retatrutide 5 mg + Cagrilintide 5 mg from Epigenetix Labs is: Produced using solid-phase peptide synthesis (SPPS) |
| Strict Legal Disclaimer | FOR RESEARCH USE ONLY. This product is not FDA-approved and is not intended for human or veterinary use. It is not intended to diagnose, treat, cure, or prevent any disease or health condition. By purchasing this product from Epigenetix Labs, you confirm that it will be used exclusively for scientific and laboratory research, and handled by qualified professionals in an appropriate setting. Do not inject, ingest, or apply this compound outside of controlled research environments. |








Claire –
Incredibly high quality. Immediate effect and I saw results in days. Down 30lbs so far. Still lifting weights and feeling strong. The addition of the cagrilintide and purity of the product make this one exceptional.